Short answer
Cryoport, Inc. (CYRX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Cryoport announced financial results for Q3 ended September 30, 2026.
Cryoport, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Cryoport announced financial results for Q3 ended September 30, 2026
- Investors should review Exhibit 99.1 for reported revenue, profitability, cash flow and management outlook
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $50.2M, up 14%, led by Life Sciences Services growth of 18% and BioStorage/BioServices growth of 25%
- Commercial cell and gene therapy revenue increased 20%, with support for 23 approved therapies and 788 clinical trials
- Adjusted EBITDA turned positive at $1.1M versus negative $0.6M, but GAAP net loss widened to $10.9M
- Total gross margin declined to 47.5% from 48.2%, driven by Products margin falling to 43.6% from 46.4%
- Full-year 2026 revenue guidance raised to $197M-$199M, supported by 9M revenue of $147.0M, up 12%
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cryoport, Inc. 8-K filings
Get the next CYRX 8-K as it lands
Follow CYRX for push alerts, or ask the research agent what this filing means.